2014 MPN Challenge Gary Reuther
Gary Reuther, Moffitt Cancer Center
Using Pharmacological Synthetic Lethality to Treat MPNs
Selective JAK2 Inhibition
This project proposes to investigate the role of Pim1 in JAK2 positive MPNs, and explore the possibilities of combination JAK2/ Pim1 inhibitors. As we know, JAK2 inhibitors are not selective. They inhibit the body’s ability to create needed blood cells. If successful the new treatment would inhibit the over production of blood cells but allow the body to produce blood cells when needed.